TR200602095T2 - Hümanize Anti-LT-Beta-R antikorları - Google Patents

Hümanize Anti-LT-Beta-R antikorları

Info

Publication number
TR200602095T2
TR200602095T2 TR2006/02095T TR200602095T TR200602095T2 TR 200602095 T2 TR200602095 T2 TR 200602095T2 TR 2006/02095 T TR2006/02095 T TR 2006/02095T TR 200602095 T TR200602095 T TR 200602095T TR 200602095 T2 TR200602095 T2 TR 200602095T2
Authority
TR
Turkey
Prior art keywords
beta
antibodies
humanized anti
humanized
humanized antibodies
Prior art date
Application number
TR2006/02095T
Other languages
English (en)
Inventor
Gardber Ellen
W. Saldanha Jose
Lyne Paul
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of TR200602095T2 publication Critical patent/TR200602095T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LT-Beta-R'ye insancıllaştırılmış antikorlar ve bunların kullanım metodu sağlanmıştır.
TR2006/02095T 2000-10-13 2001-10-12 Hümanize Anti-LT-Beta-R antikorları TR200602095T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
TR200602095T2 true TR200602095T2 (tr) 2007-02-21

Family

ID=27399340

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2006/02095T TR200602095T2 (tr) 2000-10-13 2001-10-12 Hümanize Anti-LT-Beta-R antikorları
TR2003/00478T TR200300478T2 (tr) 2000-10-13 2001-10-12 Hümanize antiLT-ß-R antikorları

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2003/00478T TR200300478T2 (tr) 2000-10-13 2001-10-12 Hümanize antiLT-ß-R antikorları

Country Status (25)

Country Link
US (2) US7429644B2 (tr)
EP (1) EP1326897A2 (tr)
JP (1) JP2004532608A (tr)
KR (1) KR20030041164A (tr)
CN (1) CN1547590A (tr)
AR (1) AR035352A1 (tr)
AU (2) AU2002211747B2 (tr)
BG (1) BG107802A (tr)
BR (1) BR0114646A (tr)
CA (1) CA2425809A1 (tr)
CZ (1) CZ20031307A3 (tr)
EA (1) EA006945B1 (tr)
EE (1) EE200300179A (tr)
GE (1) GEP20063752B (tr)
HU (1) HUP0302573A2 (tr)
IL (1) IL155340A0 (tr)
IS (1) IS6779A (tr)
MX (1) MXPA03003144A (tr)
NO (1) NO20031642L (tr)
NZ (1) NZ525793A (tr)
PL (1) PL366307A1 (tr)
SK (1) SK5672003A3 (tr)
TR (2) TR200602095T2 (tr)
WO (1) WO2002030986A2 (tr)
YU (1) YU28503A (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006513225A (ja) * 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
CA2652733C (en) * 2006-05-25 2016-06-21 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
JP2010506955A (ja) * 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN106188303A (zh) 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
RS59340B1 (sr) 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
IL256800B2 (en) 2015-07-14 2023-04-01 Immunext Inc An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
CN115594759B (zh) * 2021-07-08 2026-04-24 洛阳普泰生物技术有限公司 犬轮状病毒单克隆抗体对及其应用
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
KR20250169609A (ko) 2023-04-07 2025-12-03 리제너론 파마슈티칼스 인코포레이티드 림포톡신 β 수용체 작용제를 이용한 암 치료 방법
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992000329A1 (en) 1990-06-27 1992-01-09 Biogen, Inc. Surface complexed lymphotoxin
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69334224D1 (de) 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
CN1900116A (zh) * 1995-01-26 2007-01-24 拜奥根Idec马萨诸塞公司 抗－LT－β－R抗体、含有该抗体的药用组合物及其制药应用
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
ES2211035T3 (es) 1998-01-30 2004-07-01 Biogen, Inc. Tratamiento de linfomas foliculares usando inhibidores de la ruta de la linfotoxina (lt).
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006513225A (ja) * 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子

Also Published As

Publication number Publication date
CZ20031307A3 (cs) 2003-10-15
US7429644B2 (en) 2008-09-30
AR035352A1 (es) 2004-05-12
WO2002030986A2 (en) 2002-04-18
AU2002211747B2 (en) 2007-11-29
EA200300464A1 (ru) 2003-10-30
AU1174702A (en) 2002-04-22
KR20030041164A (ko) 2003-05-23
NO20031642L (no) 2003-06-13
SK5672003A3 (en) 2003-10-07
US20040058394A1 (en) 2004-03-25
JP2004532608A (ja) 2004-10-28
EE200300179A (et) 2003-08-15
CN1547590A (zh) 2004-11-17
US20090092601A1 (en) 2009-04-09
EA006945B1 (ru) 2006-06-30
MXPA03003144A (es) 2004-12-06
BG107802A (bg) 2004-01-30
GEP20063752B (en) 2006-02-27
PL366307A1 (en) 2005-01-24
NO20031642D0 (no) 2003-04-10
EP1326897A2 (en) 2003-07-16
YU28503A (sh) 2006-05-25
CA2425809A1 (en) 2002-04-18
TR200300478T2 (tr) 2004-10-21
HUP0302573A2 (hu) 2003-10-28
WO2002030986A3 (en) 2003-03-13
NZ525793A (en) 2008-04-30
BR0114646A (pt) 2006-02-21
IS6779A (is) 2003-04-11
IL155340A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATE264863T1 (de) 28-epirapaloge
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
EP1572077A4 (en) USES OF MONOCLONAL ANTIBODY 8H9
EE200000642A (et) Suurendatud saagisega FAPalfa-spetsiifilised antikehad
EP1372718A4 (en) PREPARATION AND USE OF NEW PEPTIDE BASED AGENTS FOR USE WITH BISPECIFIC ANTIBODIES
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
ITMI20011986A0 (it) Metodo e composizione per l'attivazione di cellule presentanti l'antigene
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
DE60140516D1 (de) Behandlung von fluorkohlenstoff- ausgangsmaterialien
NO20032542D0 (no) Dempede anti-CD28-antistoffer og anvendelse derav
NO20031860D0 (no) Kahalaolid F
EP1267930A4 (en) CROSS-REACTION DISPLACEMENT ANTIBODIES FROM COLLAGEN BINDING PROTEINS AND METHOD OF IDENTIFICATION AND USE
BR0015872A (pt) Agentes antitrombóticos
BR0110577A (pt) Decorina transgenicamente produzida
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
BR0110902A (pt) Inibidores de mmp-9/mmp-2
DE60139694D1 (de) Menschliche myelom zelllinie
BR0316544A (pt) Compostos calcilìticos
MY133881A (en) "calcilytic compounds"
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies